Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases

Fig. 2

Drug sensitivity analyses of a medium throughput drug library. (A, upper panel) GRDSS of 33 drugs in T1–T5 (colored dots) as compared to the reference PDO lines (grey dots, n = 46). (A, lower panel) Mean GRDSS of 33 drugs in T1–T5 centered to the mean of the entire dataset (n = 51). The grey line within the bars indicates standard deviation of the respective drug’s GRDSS for T1–T5 lesions. B Drug activities of 5-FU, oxaliplatin, SN-38 (active metabolite of irinotecan) as single agents and combination therapies in T1-T5 PDOs. C Scatter plots of 5-FU drug sensitivity scores (growth rate adjusted) and GSVA scores of signatures of 5-FU sensitivity and resistance in PDOs from this patient (colored as indicated) and a reference PDO dataset (grey). D EGFR inhibitor activities and their association with RAS/RAF mutation status analyzed in 23 mutated and 28 wild type PDOs. GRDSS—Growth adjusted drug sensitivity scores, 5-FU 5-fluorouracil, FLV 5-FU + 10 μM leucovorin, FLOX 5-FU and oxaliplatin at 1:1 ratios + 10 μM leucovorin, FLIRI 5-FU and SN-38 at 100:1 ratios + 10 μM leucovorin, GSVA—gene set variation analysis

Back to article page